Novo Nordisk A/S (NVO)
43.07
-0.94
(-2.14%)
USD |
NYSE |
Sep 11, 16:00
43.30
+0.23
(+0.53%)
Pre-Market: 06:10
Novo Nordisk Enterprise Value : 158.66B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 158.66B |
| September 10, 2026 | 161.80B |
| September 09, 2026 | 163.64B |
| September 08, 2026 | 165.65B |
| September 04, 2026 | 170.47B |
| September 03, 2026 | 173.52B |
| September 02, 2026 | 171.04B |
| September 01, 2026 | 165.52B |
| August 31, 2026 | 166.22B |
| August 28, 2026 | 167.16B |
| August 27, 2026 | 169.33B |
| August 26, 2026 | 172.44B |
| August 25, 2026 | 177.36B |
| August 24, 2026 | 171.54B |
| August 21, 2026 | 170.94B |
| August 20, 2026 | 168.93B |
| August 19, 2026 | 170.07B |
| August 18, 2026 | 167.49B |
| August 17, 2026 | 164.72B |
| August 14, 2026 | 168.09B |
| August 13, 2026 | 170.87B |
| August 12, 2026 | 169.77B |
| August 11, 2026 | 172.38B |
| August 10, 2026 | 174.25B |
| August 07, 2026 | 172.68B |
| Date | Value |
|---|---|
| August 06, 2026 | 168.36B |
| August 05, 2026 | 163.54B |
| August 04, 2026 | 162.71B |
| August 03, 2026 | 172.11B |
| July 31, 2026 | 172.08B |
| July 30, 2026 | 187.23B |
| July 29, 2026 | 187.13B |
| July 28, 2026 | 185.06B |
| July 27, 2026 | 180.74B |
| July 24, 2026 | 177.73B |
| July 23, 2026 | 175.76B |
| July 22, 2026 | 175.79B |
| July 21, 2026 | 179.77B |
| July 20, 2026 | 180.54B |
| July 17, 2026 | 182.92B |
| July 16, 2026 | 186.80B |
| July 15, 2026 | 183.72B |
| July 14, 2026 | 178.73B |
| July 13, 2026 | 179.44B |
| July 10, 2026 | 180.11B |
| July 09, 2026 | 178.10B |
| July 08, 2026 | 178.13B |
| July 07, 2026 | 180.64B |
| July 06, 2026 | 179.37B |
| July 02, 2026 | 183.29B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 523.09B |
| GSK Plc | 116.82B |
| Johnson & Johnson | 667.86B |
| Eli Lilly & Co. | 1.096T |
| Merck & Co., Inc. | 402.09B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.265B |
| Revenue (Quarterly) | 12.21B |
| Total Expenses (Quarterly) | 8.946B |
| EPS Diluted (Quarterly) | 0.7362 |
| Gross Profit Margin (Quarterly) | 78.21% |
| Profit Margin (Quarterly) | 26.74% |
| Earnings Yield | 9.50% |
| Operating Earnings Yield | 12.19% |
| Normalized Earnings Yield | 9.883 |